Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06533579 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
A Phase 1 study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma, sponsored by Vironexis Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 8
- Study locations
NCT06533579 is a Phase 1 study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma that is actively recruiting participants, run by Vironexis Biotherapeutics. The registered enrollment target is 32 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (82% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT06533579, a Phase 1 study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma, is actively recruiting participants, sponsored by Vironexis Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
Conditions Studied
Interventions
- GENETIC Dose Level 1, VNX-101
- GENETIC Dose Level 2, VNX-101
- GENETIC Dose Level 3, VNX-101
- GENETIC Dose Level 4, VNX-101
Study Locations (8)
California
- City of Hope - Duarte
- Valkyrie Clinical Trials - Los Angeles
Colorado
- Colorado Blood Cancer Institute - Denver
New York
- New York Medical College - Valhalla
North Carolina
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center - Chapel Hill
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Tennessee
- TriStar BMT - Nashville
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-05-30 |
| Est. Completion | 2031-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06533579
The ClinicalTrials.gov registry entry for NCT06533579 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (82% lower). The listed sponsor is Vironexis Biotherapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 4 interventions - of which Dose Level 1, VNX-101 is the first listed.
NCT06533579 reports 8 study locations spanning 7 distinct geographic areas - top geographies include California, Colorado, New York.
Frequently Asked Questions
What is clinical trial NCT06533579 about?
NCT06533579 is a clinical study titled "Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)". This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
What is the current status of trial NCT06533579?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-05-30. Estimated completion is 2031-09.
What conditions does trial NCT06533579 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma.
What interventions are being tested in trial NCT06533579?
The interventions under investigation include: Dose Level 1, VNX-101 (GENETIC), Dose Level 2, VNX-101 (GENETIC), Dose Level 3, VNX-101 (GENETIC), Dose Level 4, VNX-101 (GENETIC).
Who is sponsoring clinical trial NCT06533579?
This trial is sponsored by Vironexis Biotherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06533579 being conducted?
This trial has 8 study locations across California, Colorado, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Explore more on PlainTrial
Chronic Lymphocytic Leukemia
All registered trials for this condition
Diffuse Large B Cell Lymphoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.